Loading...
Market
Number of new competitors for Dupixent in COPD by end of 2024?
2
Resolution / Starting Odds
No new competitors • 33%
1 new competitor • 33%
2 or more new competitors • 34%
FDA and EMA (European Medicines Agency) approvals
Story
Sanofi and Regeneron’s Dupixent Approved for COPD, 'Smoker's Lungs,' in EU
Jul 3, 2024, 05:15 AM
Sanofi and its partner Regeneron have received European Union approval on Wednesday for the expanded use of their Dupixent injection to treat patients with chronic obstructive pulmonary disease (COPD). This marks the first-ever targeted therapy for COPD, also referred to as 'smoker's lungs,' approved in the EU. Notably, the EU's approval process for Dupixent was faster than that of the United States, highlighting a rare instance of expedited clearance. The approval is expected to create a new growth avenue for the blockbuster drug.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
More than 3 competitors • 25%
2 to 3 competitors • 25%
1 competitor • 25%
No new competitors • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
No new competitors • 25%
1-2 new competitors • 25%
3-4 new competitors • 25%
5+ new competitors • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%